Skip to main content Skip to footer

Beyond the Small Molecule: Characterizing Peptide, Protein, and Nucleic Acid Therapeutics

The rapid growth of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the treatment of diabetes and obesity has increased the need for robust analytical methods capable of separating and quantifying closely related impurities. These impurities, which can arise from synthesis or degradation pathways, often differ from the active pharmaceutical ingredient (API) by only a single amino acid substitution, oxidation, deamidation, truncation, or stereochemical change. 

Please select a product of interest:
Would you like more information about the benefits of a CHROMacademy Premier membership?


For full details of how Agilent will treat your information please click here to view Agilent's privacy policy.